Johnson & Johnson announced a more than $1 billion investment to build a cell‑therapy manufacturing facility in Pennsylvania as part of a broader push to expand its cell therapy capabilities. The site will support production capacity for next‑generation cell and gene therapies and strengthen J&J’s end‑to‑end manufacturing footprint. The investment signals Big Pharma’s continued emphasis on onshore manufacturing for advanced‑therapy products and reflects industry efforts to secure scale, supply resiliency and regulatory readiness as more cell therapies approach later‑stage clinical development and commercialization.